A tier-graded review of 13 popular wellness practices against the clinical evidence — what works, what is overstated, and what the $6.8 trillion industry is selling without proof.
The $6.8 Trillion Marketplace
An industry larger than pharmaceuticals, sport and the green economy
The global wellness economy reached $6.8 trillion in 2024 — ✓ Established — overtaking the green economy ($5.1 trillion), tourism ($5 trillion), and information technology ($5.3 trillion), and standing roughly four times larger than the entire pharmaceutical industry [1]. It is the fastest-growing consumer category of the decade, projected to hit $9.8 trillion by 2029 [1]. The scale matters because it shapes incentives — and because most of the products and services inside that figure operate outside the regulatory architecture built for medicine.
The Global Wellness Institute, the industry body that produces the most-cited market data, defines wellness across eleven sectors: physical activity, healthy eating and weight loss, beauty and personal care, mental wellness, traditional and complementary medicine, public health, wellness tourism, wellness real estate, spas, thermal/mineral springs, and workplace wellness [1]. The composite figure is dominated by personal care and beauty, healthy eating, and physical activity — but the fastest growth is occurring in mental wellness apps, supplements making structure-function claims, and a constellation of in-clinic services that sit between medicine and lifestyle: IV drips, hyperbaric oxygen, peptide injections, full-body MRI scans, cold plunges, infrared saunas.
The economic significance is now structural. Wellness represented 6.1% of global GDP in 2024 [1] — comparable to global manufacturing of motor vehicles. In the United States, the sector grew 7.9% from 2023 to 2024, outpacing GDP growth by a factor of more than three. Wellness has doubled in size since 2013. The investor pitch is durable: it sells consumables (supplements, juices, powders), consumer durables (red-light panels, cold plunges, standing desks), services (meditation apps, spa visits, IV clinics), and content (podcasts, books, courses). It has a celebrity engine, an influencer economy, and — increasingly — a venture capital pipeline.
Yet the wellness industry is not monolithic in its evidentiary status. ✓ Established exercise reduces all-cause mortality. Mediterranean-pattern eating reduces cardiovascular events. Sleep deprivation impairs cognition. These are not contested [11]. Other elements — saunas, certain meditation practices, some adaptogenic herbs — show clinically meaningful but modest effects in well-conducted trials [6][7][11]. A third tier — IV vitamin drips for healthy people, blue-light filtering glasses, jade vaginal eggs — has been tested and found to produce no clinically meaningful effect, or has never been tested at all [3][5][15].
The Global Wellness Institute estimates the wellness economy at $6.8 trillion in 2024 — versus the global pharmaceutical industry's roughly $1.8 trillion [1]. Wellness now exceeds tourism, sport, and IT by individual sector. Yet pharmaceutical products undergo phased clinical trials, FDA premarket review, post-marketing surveillance, and prescriber accountability. The bulk of the $6.8 trillion wellness market faces none of these.
The asymmetry is the story. A $1.8 trillion industry is required to demonstrate efficacy and safety to regulatory standards before a product reaches patients. A $6.8 trillion industry is required only to avoid making explicit disease-treatment claims. The result is a market in which two products with similar packaging, similar marketing, and similar price points may have been tested in tens of thousands of patients across decades — or never tested at all. The consumer is rarely positioned to tell which is which.
This report grades thirteen of the most popular wellness practices against the clinical evidence. The categories are not arbitrary. They follow the framework used by the Cochrane Collaboration and major medical bodies: tier-fact (replicated, large-sample, independently-funded evidence of clinically meaningful effect), tier-strong (consistent evidence with moderate quality or limited generalisability), and tier-contested (disputed effects, methodological problems, or industry-conflict-of-interest concerns) [3][8]. The framework matters because the wellness industry's primary commercial advantage is not falsehood — it is ambiguity. A practice that works in 30% of users sounds the same in marketing as one that works in 90%. Consumers, regulators and clinicians need a tier-graded map.
The remainder of this report constructs that map.
Why Wellness Claims Don't Need Proof
The DSHEA architecture and the structure-function loophole
Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), the United States Food and Drug Administration has no authority to require premarket approval for dietary supplements — ✓ Established [12]. Manufacturers may bring products to market without notifying the FDA at all, provided ingredients were marketed before 1994 or qualify under the structure-function claim standard. Most wellness products globally inherit a regulatory framework built around this same logic: claims about supporting bodily structures or functions do not require the same evidence as claims to treat disease.
The legal architecture is consequential. A drug, in the United States, must pass three phases of human clinical trials, demonstrate efficacy versus placebo, and prove acceptable safety before it can be sold [12]. Average development cost: $1–2 billion. Average timeline: ten to fifteen years. A dietary supplement, by contrast, requires no clinical trial at all. The manufacturer is responsible for the safety of its ingredients but does not have to share that evidence with the FDA before selling. The FDA can act post-market only if it can demonstrate that a product presents a "significant or unreasonable risk of injury or illness" — a high evidentiary bar that the agency has rarely cleared at scale [12].
The mechanism that allows wellness companies to make health-adjacent claims without medical-grade evidence is the structure-function claim. A drug claim — "treats hypertension" — triggers premarket review. A structure-function claim — "supports cardiovascular health" — does not. The semantic distance between these phrases is small; the regulatory distance is enormous. Manufacturers structure marketing around the second formulation. The required disclaimer — "this statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease" — appears in small print and is rarely read by consumers [12].
Under DSHEA, dietary supplements do not undergo any FDA review before sale. Manufacturers self-certify safety; the agency must demonstrate harm post-market before requiring withdrawal [12]. As a result, FDA identified 776 supplements adulterated with unapproved pharmaceutical ingredients — including sildenafil, sibutramine, and anabolic steroids — between 2007 and 2016, most of which remained on store shelves after agency warnings [12].
The structure-function loophole is then amplified by a second mechanism: the wellness service. IV vitamin drips, cold plunges, infrared sauna sessions and red-light panels are not consumed as products but delivered as services. Services are regulated where they are delivered — in the United States, primarily at state level — and standards vary wildly. A "med spa" may be operated by a registered nurse under physician oversight in one state and by an unlicensed technician in another. The FDA's January 2024 alert on IV mixtures at unregulated med spas warned of unsanitary compounding, improper sterilisation, and unlicensed administrators [5]. No federal licensure exists.
The third mechanism is jurisdictional fragmentation. The FDA regulates supplements for safety; the Federal Trade Commission regulates advertising claims; state attorneys general handle consumer-protection cases; the CDC tracks adverse events. None of these bodies has comprehensive authority. The FTC's most prominent recent enforcement actions — $27.6 million returned to Prevagen consumers in 2024, refunds to 536,000 consumers deceived by Sobrenix's alcohol-craving claims — recovered a fraction of revenue and arrived years after products were marketed [14]. Enforcement is reactive and resource-constrained against a $6.8 trillion target.
A pharmaceutical claim — "lowers blood pressure" — triggers $1 billion of mandated trials. A wellness claim — "supports healthy circulation" — triggers nothing. The two products may be sold side-by-side with similar packaging, similar pricing and similar implied benefits. Consumers cannot reliably distinguish them. The result is a regulatory architecture that treats words, not effects, as the relevant unit of consumer protection.
The argument that DSHEA reflects considered policy is defended by the supplement industry on the grounds that vitamins, minerals, and traditional herbs do not need drug-level testing. The argument has surface plausibility for centuries-used substances at long-established doses. It collapses for novel ingredients, concentrated extracts, megadoses, and combinations — all of which are now sold under the same regulatory umbrella. Ashwagandha at 120 mg in a tea is not the same product as a 1,000 mg standardised extract sold for stress relief [7]. DSHEA treats them identically.
Outside the United States, the picture is mixed but no more reassuring for the consumer seeking evidence-based products. The European Food Safety Authority (EFSA) requires premarket evaluation of health claims under EC Regulation 1924/2006, and rejects the majority — over 80% of the more than 44,000 health claims submitted have been refused for inadequate evidence. Yet enforcement against unauthorised claims remains national and uneven. In the United Kingdom, supplement claims are governed by the Advertising Standards Authority, with similar gaps. Australia's Therapeutic Goods Administration applies a lighter "listed medicine" review that requires evidence of safety but accepts traditional-use claims for efficacy.
The pattern across three decades is consistent. Regulators defer; the industry expands; evidence accumulates against specific claims; enforcement actions arrive years late and recover small fractions of revenue. The architecture does not produce systematic deception. It produces systematic ambiguity — and the ambiguity, in commercial terms, is the product.
What the Evidence Actually Supports
The tier-fact wellness practices: replicated, generalisable, clinically meaningful
A subset of widely-marketed wellness practices is supported by replicated, large-sample, independently-funded evidence of clinically meaningful effect. The list is shorter than wellness marketing implies — but it is not empty [8][11][13]. Identifying these practices and separating them from the rest is the central work of consumer health literacy.
Three practices meet the highest evidentiary tier. The first is intermittent fasting in its time-restricted-eating form. A March 2024 umbrella review in eClinicalMedicine synthesised systematic reviews and meta-analyses of randomised trials and concluded that time-restricted eating produces 5.5–6.5 kg weight loss at six months, accompanied by reductions in fasting insulin and HbA1c [8] — ✓ Established. The clinically important finding is what intermittent fasting is not: it is not superior to continuous caloric restriction. The benefit is comparable to traditional dieting; the mechanism appears to be reduced caloric intake rather than a metabolic shift induced by fasting itself.
The second is regular sauna bathing — but the evidence is for traditional Finnish sauna, not infrared. The Mayo Clinic Proceedings review of Finnish prospective-cohort data found that 4–7 sauna sessions per week were associated with 50% lower cardiovascular mortality versus a single weekly session, controlling for known confounders [11]. The plausible mechanism is repeated vasodilation, reduced systemic blood pressure, improved endothelial function, and modulation of the autonomic nervous system. The effect is large and biologically coherent. The infrared sauna market — which has aggressively marketed cellular detoxification, weight loss, and immune-boosting claims — does not share this evidence base. Infrared sauna trials are smaller, shorter, and primarily focused on cardiac populations.
A systematic review of randomised trials evaluating Headspace and Calm found that 75% of Headspace trials showed reduction in depression versus control, with effect sizes typically in the small-to-moderate range (Cohen's d 0.2–0.5) [6]. The same review documented industry funding, author conflicts of interest and selective outcome reporting in a substantial fraction of studies — meaning the effect is real but the magnitude is probably overestimated.
The third is mindfulness meditation delivered through evidence-tested apps. Headspace, the most heavily-studied app, has shown reduction in depressive symptoms in 75% of randomised controlled trials evaluating it [6]. Effect sizes are modest — Cohen's d typically 0.2–0.5, the range for "small-to-moderate" effects — but consistent enough across studies to constitute strong evidence. The relevant qualification is that the literature is not industry-independent: a substantial portion of trials are funded, co-authored, or facilitated by Headspace or related entities. The 2022 systematic review in JMIR Mental Health flagged this conflict-of-interest pattern explicitly [6]. The likely effect is real; the magnitude is probably overestimated.
Standing desks — the workplace-wellness intervention closest to evidence-based — produce consistent reductions in sitting time of 60–90 minutes per day in randomised trials, with corresponding improvements in self-reported back and neck pain at three to six months. The cardiometabolic benefit, while measurable, is small: standing burns roughly 0.15 kcal/min more than sitting, a difference that adds approximately 50 kcal across a workday. The intervention's value is in reducing prolonged static posture, not in burning calories. The 2024 University of Sydney evidence on prolonged standing — that more than two hours continuous standing increases circulatory complications — has refined, not refuted, the standing-desk recommendation. The current evidence-based prescription is rotation, not standing.
"The benefit is comparable to continuous caloric restriction, not superior. The differences observed are not clinically significant. Despite the existence of multiple modes of intermittent fasting, there is no conclusive evidence as to which mode is the most effective and safe."
— Patikorn et al., Intermittent Fasting Umbrella Review, eClinicalMedicine (Lancet), March 2024 [8]Adaptogenic herbs — particularly ashwagandha and rhodiola rosea — sit at the boundary of tier-strong and tier-contested. Seven randomised controlled trials of ashwagandha across 491 adults, all from India, showed reductions in perceived stress, serum cortisol, and self-reported anxiety symptoms over 6–8 weeks [7]. The European Medicines Agency approved rhodiola for traditional use in stress-related fatigue in 2011. The evidence is preliminary but consistent. The qualifications are substantial: the populations studied are narrow, the durations short, the effect sizes modest, and rare cases of ashwagandha-induced hepatotoxicity have been documented [7]. The product category is far better characterised than most wellness supplements, but the marketing extrapolates the data substantially beyond what trials demonstrate.
Photobiomodulation — the clinical term for red-light and near-infrared therapy — has the strongest dermatology evidence within the consumer-facing wellness category. A 2025 multidisciplinary consensus in the Journal of the American Academy of Dermatology found strong evidence for acne vulgaris, androgenetic alopecia (hair regrowth), and reducing side effects of cancer treatment such as oral mucositis [13]. The cellular mechanism — cytochrome c oxidase activation in mitochondria — is plausible and supported by in vitro data. Evidence for general "skin rejuvenation" claims, pain relief, and weight loss is mixed-to-weak, with wide variation in irradiance and wavelength making cross-study comparison impossible [13].
The pattern across these tier-fact and tier-strong practices is instructive. None of them work in the way wellness marketing implies. Intermittent fasting is not metabolic alchemy; it is caloric restriction by another name. Sauna bathing is not detoxification; it is repeated cardiovascular stress. Meditation apps do not produce profound enlightenment; they produce modest, durable improvements in depressive symptoms. Red-light therapy does not reverse aging; it has narrow, well-defined dermatology applications. The science supports specific, modest, mechanism-grounded claims. The marketing supports something larger and shinier. The gap between the two is the wellness industry's commercial space.
What the Evidence Partly Supports
The tier-strong-but-overstated and tier-contested categories
A second tier of wellness practices is supported by evidence — but evidence narrower, weaker, or more methodologically compromised than the marketing implies. ✓ Established small short-term effects exist for cold-water immersion, breathwork, certain supplements, and infrared sauna exposure [2][10]. The clinical question is whether modest, transient effects justify the price points, time commitments, and lifestyle reorganisations that the practices demand.
Cold plunges have become the signature wellness practice of the 2020s — popularised by athletes, podcasters, and venture capitalists, with cold-plunge tanks now retailing for $5,000 to $15,000. The evidence base is real but narrow. The most rigorous synthesis to date is the 2024 PLOS One meta-analysis by Yankouskaya et al., covering 11 studies and 3,177 participants [2]. The pooled finding: cold-water immersion (≤15°C, ≥30 seconds, chest-high) produces measurable reductions in stress 12 hours post-immersion, modest improvements in sleep quality, and reductions in self-reported sick days. The pooled finding also: quality-of-life improvements were no longer statistically significant at three months, and short-term inflammation markers actually increased in the immediate post-immersion period [2].
The marketed claims — that cold plunges "reset" the nervous system, treat depression, accelerate metabolic recovery, or boost immune function — receive partial support at best. The "boost dopamine 250%" claim popularised in podcast culture rests on a single 2000 study of 10 male volunteers conducted at 14°C for one hour, a protocol almost no consumer plunge approximates [2]. The athletic-recovery literature is more equivocal: ice baths after resistance training appear to impair muscle protein synthesis and hypertrophy. Cold exposure is real physiology; the breadth of marketed effects is not.
Breathwork — particularly the Wim Hof Method (WHM), combining hyperventilation, breath-holding and cold exposure — has accumulated a real but methodologically thin literature. The first systematic review, published in 2024, identified nine papers and eight individual trials with 15 to 48 participants each, 86.4% male [10]. The findings: WHM may reduce inflammation markers via epinephrine spike, may improve some psychological measures, and produces no obvious safety problems in healthy adults. The reviewers' overall assessment: "the quality of the studies is very low, meaning that all the results must be interpreted with caution" [10] — ⚖ Contested. The practice is not without merit, but the marketing — that WHM cures autoimmune disease, depression, or chronic illness — exceeds what the evidence supports by a substantial margin.
Collagen supplementation occupies a particularly instructive evidentiary position. A 2025 meta-analysis in the American Journal of Medicine pooled 23 randomised controlled trials of collagen for skin aging across 1,474 participants. The headline finding: collagen supplements significantly improved skin hydration, elasticity, and wrinkles versus placebo [4]. The qualifying finding: when the analysis was stratified by funding source, trials not funded by collagen manufacturers showed no significant effect on any of those measures. Industry-funded trials drove the entire effect [4]. This is one of the cleanest demonstrations of funding bias in the wellness literature — the existence of a positive overall result, contingent entirely on conflict-of-interest-laden studies.
When a randomised-trial body produces a positive effect that disappears the moment industry-funded studies are excluded, the rational interpretation is that the effect is small or absent and the funded literature is overstating it. Collagen supplements meet this profile precisely. The same pattern appears in glucosamine for arthritis, omega-3 for cognition in healthy adults, and several adaptogens at the strong end of the supplement category.
Infrared saunas occupy a tier-strong position with substantial qualification. The Mayo Clinic Proceedings review of sauna evidence is dominated by traditional Finnish sauna data, where the cardiovascular-mortality benefit is robust [11]. Infrared-specific data is much thinner: smaller trials, often industry-funded, with cardiac patient populations and short follow-up. The plausibility of cross-modality extrapolation is moderate — both modalities induce thermoregulatory stress — but the assumption that infrared sauna produces equivalent cardiovascular benefits to Finnish sauna is not established. Infrared marketing also makes claims (cellular detoxification, weight loss, immune boosting) that have no evidence base in either modality.
Probiotic supplements — a separate $60+ billion category — produce conditional evidence. Specific strains have demonstrated efficacy for specific conditions: Lactobacillus rhamnosus GG for antibiotic-associated diarrhoea, certain Bifidobacterium strains for irritable bowel syndrome subtypes, fecal microbiota transplant for recurrent Clostridioides difficile infection. The 2024 American Gastroenterological Association guidelines explicitly decline to recommend probiotics for general health in healthy adults. A 2018 Cell study found that two-thirds of healthy adults are "resisters" — probiotics did not colonise their gut and produced no measurable microbiota or symptom change. The marketed concept of "boosting gut health" with a generic probiotic is not supported by the evidence; targeted strain-condition matching is.
The pattern across this tier is consistent. A real physiological effect exists. The effect is smaller, narrower, and more methodologically uncertain than marketing implies. Industry funding inflates the apparent effect. Long-term durability is rarely demonstrated. The honest consumer position — that these practices may produce modest benefits in some users for some conditions, with quality-of-evidence concerns that warrant caution — is not the position the marketing communicates.
What the Evidence Does Not Support
The tier-empty wellness practices: tested, found wanting, still selling
A third tier of wellness practices has been formally tested at high methodological standards and found to produce no clinically meaningful effect — or has never been tested and lacks plausible mechanism. ✓ Established blue-light filtering glasses, IV vitamin therapy for healthy people, juice cleanses, jade vaginal eggs, and grounding/earthing all sit in this tier [3][5][9][15]. Their continued commercial success is a fact about the information environment, not about clinical effect.
Blue-light filtering glasses are the clearest example of a category convicted by Cochrane review. The 2023 Cochrane systematic review by Singh et al. analysed 17 randomised controlled trials and concluded that blue-light filtering lenses produce "no clinically meaningful difference" in eye strain, sleep quality, or macular protection versus standard lenses [3]. The findings explicitly do not support prescription to the general population. Yet blue-light glasses remain a multi-hundred-million-dollar category, marketed by major eyewear retailers as essential for screen-heavy lifestyles. The continued sale is regulatory, not scientific: the claims are technically structure-function ("filters blue light") rather than disease-treatment ("prevents eye strain").
IV vitamin therapy for healthy individuals is the second clear-cut case. No randomised controlled trial supports IV nutrient infusions for hangover relief, immunity boosting, energy enhancement, or anti-aging in healthy adults [5]. The FDA has not approved any wellness IV therapy. The Cleveland Clinic, Mayo Clinic, and Houston Methodist have all issued public statements warning that the marketed benefits are unsupported and that risks include infection, electrolyte imbalance, vitamin toxicity (particularly fat-soluble vitamins), and improperly compounded mixtures from unregulated med spas [5]. The FDA's January 2024 alert specifically warned about unsanitary compounding and unlicensed administration at IV clinics. The category continues to grow, with US wellness IV revenues exceeding $2 billion annually.
In September 2018, California prosecutors fined Goop $145,000 for unsubstantiated medical claims that jade and rose-quartz vaginal eggs could balance hormones, regulate menstrual cycles, prevent uterine prolapse, and increase bladder control [15]. The penalty was a small fraction of revenue from the products. Goop made no admission of liability. The product line was reformulated with revised marketing language and remained on sale. The case is the canonical demonstration of how regulatory action functions in the wellness industry: late, small, and commercially absorbable.
Juice cleanses and "detox" protocols have been comprehensively rejected by mainstream medical bodies. The National Center for Complementary and Integrative Health states there is no evidence that juice cleanses or detox diets remove toxins, improve liver function, or produce sustained health benefits. The 2025 Northwestern University study examined a three-day vegetable-fruit juice diet and found that within those three days, oral and gut microbiota shifted toward pro-inflammatory species and beneficial bacteria declined [9]. No detectable improvement in any clinical biomarker was observed. Juice cleanses do measurable harm to microbial ecology in days; the claimed benefits are not detectable at any timescale.
The grounding/earthing category — direct skin contact with the Earth's surface or with conductive mats connected to ground — has produced a small literature reporting effects on cortisol, heart-rate variability, blood viscosity, and inflammation. The literature has serious methodological problems: small samples (typically under 60 participants), frequent absence of blinding, and a striking concentration of authors and funding around individuals with commercial interests in grounding products ⚖ Contested. The physical mechanism — that skin contact transfers physiologically meaningful electron charge — is not impossible but has no independent confirmation. Major medical bodies have declined to endorse grounding for any condition. The category remains a multi-hundred-million-dollar consumer market.
Cochrane reviewed blue-light glasses and found no benefit. The FDA warned about IV drips. Northwestern showed juice cleanses harm the microbiome in three days. California fined Goop for jade-egg claims. None of these findings collapsed the relevant markets. The information ecosystem that sells wellness products operates faster than the evidence ecosystem that tests them — and the regulatory ecosystem operates slowest of all. The lag is the commercial opportunity.
The jade-egg case deserves attention as a structural example. California prosecutors fined Goop $145,000 in 2018 — a sum smaller than the company's likely annual revenue from the products [15]. The settlement included no admission of liability. The product was relaunched with revised marketing language and remained on sale. The total recovery for consumers was reportedly under $200,000, distributed via refund. Compared to Goop's broader business — which has raised over $250 million in venture capital and operates a media-commerce empire — the regulatory action functioned as a cost of doing business, not a deterrent. This is the modal outcome of wellness-industry enforcement.
Hyperbaric oxygen therapy for non-FDA-approved indications, full-body MRI scans for healthy people (which the American College of Radiology specifically advises against because of false-positive rates), peptide injections sold without prescription, and most "biohacking" interventions sit in similar evidentiary positions: no replicated, large-sample, independently-funded evidence of clinically meaningful benefit. They share a marketing template — adopted by athletes, executives, and media figures — that signals scientific seriousness while operating outside the actual scientific literature.
The unifying feature of this tier is that the products do not need evidence to sell. They need narrative coherence, social proof, and an information environment that does not transmit Cochrane reviews efficiently. The wellness industry has constructed all three. The evidence environment has not yet produced an effective response.
The Funding Bias Problem
What happens when industry-funded studies are removed from the evidence base
Across the wellness literature, a recurring pattern emerges: positive overall meta-analytic effects that disappear, attenuate, or reverse when industry-funded studies are excluded from the analysis. The collagen-skin-aging meta-analysis published in 2025 is the cleanest demonstration [4]. The pattern recurs across mindfulness apps, glucosamine, omega-3, several adaptogens, and probiotic strains. ✓ Established Fact the wellness evidence base is not industry-independent in any meaningful sense.
Funding bias in wellness research has three primary mechanisms. The first is direct funding bias: industry-sponsored trials are designed, conducted, and analysed by researchers whose grants depend on the sponsor. Studies show systematically larger effect sizes, less rigorous comparators (often inactive placebo rather than active control), and selective outcome reporting (publishing the outcomes that performed favourably, omitting those that did not). The 2025 collagen meta-analysis demonstrated this with rare clarity: the effect existed in industry-funded trials and disappeared in independent ones [4].
The second mechanism is publication bias. Journals are more likely to publish positive results than null findings. In the wellness literature, where trial sponsors are often the manufacturer, negative trials may simply not be submitted. This creates an asymmetry in the published evidence base that systematically overstates apparent effect sizes. The standard remedy — pre-registration of trials before they begin, with mandatory publication of results — is implemented inconsistently in the wellness category. Many supplement trials are not registered at all.
The third mechanism is industry control of the evidence ecosystem itself. Trade associations such as the Council for Responsible Nutrition produce review papers, sponsor scientific conferences, and fund educational materials for clinicians. The work product is not always wrong, but it systematically frames wellness products favourably. Researchers who depend on industry funding for laboratory operations face structural pressure to maintain favourable relationships. The result is not fraud; it is a slow drift in the centre of gravity of the literature toward results that sustain the industry.
The conflict-of-interest patterns in wellness trials are not unique to wellness — pharmaceutical research has comparable issues — but the wellness category has weaker structural countermeasures. Pharmaceutical trials must be pre-registered, must report all outcomes, and face FDA review of the totality of evidence before approval. Supplement trials face none of these. The asymmetry between regulatory rigour and commercial scale produces a distinctive outcome: a $6.8 trillion industry whose primary scientific defence rests on a literature it largely funds.
| Risk | Severity | Assessment |
|---|---|---|
| Funding bias inflating effect sizes | Demonstrated empirically across collagen, mindfulness apps, glucosamine, omega-3 cognition trials, and several adaptogens. The collagen 2025 meta-analysis is the cleanest natural experiment. | |
| Publication bias / unregistered trials | Most supplement trials are not registered on ClinicalTrials.gov before initiation. Negative findings disproportionately unpublished. Effect estimates systematically biased upward. | |
| Adulteration with prescription pharmaceuticals | FDA documented 776 adulterated supplements (2007–2016) including sildenafil, sibutramine, anabolic steroids. Recalls voluntary. Many products remained on shelves after agency warnings. | |
| Wellness IV / med-spa contamination | FDA January 2024 alert: unsanitary compounding, unlicensed administrators, improperly sterilised mixtures. State licensure varies; federal oversight absent. | |
| False-positive cascade from full-body screening | American College of Radiology specifically advises against whole-body MRI for asymptomatic individuals. False-positive rates drive unnecessary biopsies, downstream procedures, and patient harm. |
The risk profile above clarifies the consumer's actual exposure. The most-marketed wellness practices do not produce clinically meaningful harm in healthy users at typical doses — the risk is primarily financial and opportunity-cost, not medical. The exceptions matter: adulterated supplements, IV mixtures from unregulated clinics, and screening protocols that produce cascading false-positive harms are real safety risks, not just commercial issues. The wellness industry's safety record is not catastrophic, but it is not what the marketing implies.
The honest reading of the funding-bias evidence is that the published wellness literature is consistently more favourable to wellness products than the underlying biological reality. The bias is not uniform — some practices (sauna, time-restricted eating, specific photobiomodulation indications) survive even rigorous independent assessment. But the systematic tilt is well-documented, and consumers and clinicians who treat the published evidence as a neutral guide are systematically misled. The remedy is structural, not individual: independent funding mechanisms, mandatory pre-registration, consolidated regulatory authority. None of these exists at scale in the wellness category.
The Information Ecosystem
Why the evidence does not reach the consumer
A 2024 study of TikTok health and wellness content found that 32% of analysed posts were produced by non-expert influencers, while registered dietitians produced 5%. Of the influencer content, weight-loss posts — 34% of nutrition material — had a 28% rate of being entirely inaccurate. The platform's recommendation algorithms preferentially distribute the high-engagement content, and the high-engagement content systematically deviates from evidence-based guidance. This is not an information failure. It is an information design.
The wellness information ecosystem is now structurally tilted away from evidence. Three forces produce this. The first is platform incentive structure: social-media platforms reward content that generates time-on-platform, not content that is accurate. A TikTok video promising a three-ingredient cure for inflammation outperforms a video explaining a Cochrane review of the same intervention. Algorithmic distribution amplifies the gap; over time, the influencer ecosystem selects for personalities and formats that produce the highest engagement, which correlates negatively with epistemic rigour.
The second force is the financial incentive structure for wellness influencers. TikTok's creator-rewards programme, Instagram's affiliate-marketing infrastructure, and the broader influencer economy all monetise reach. Wellness influencers monetise via affiliate links to supplement brands, sponsored posts, branded merchandise, paid courses, and direct-to-consumer product launches. The economic dependency produces a structural bias toward products that pay commissions — which are disproportionately the products with the largest marketing budgets, which are disproportionately the products with the weakest evidence base.
"TikTok is dominated by non-expert content creators, with health and wellness influencers comprising 32% of the sample. In contrast, dietitians represented only 5% of analysed posts but produced the most accurate content, with 42% being completely accurate. Weight-loss posts had the highest proportion of completely inaccurate information at 28%."
— #WhatIEatinaDay: Quality, Accuracy, and Engagement of Nutrition Content on TikTok, 2024 reviewThe third force is the production cost asymmetry between accurate and misleading content. Producing a 30-second video summarising a Cochrane review correctly requires reading the review, understanding the methods, and translating clinical statistics into accessible language. Producing a 30-second video claiming that a particular supplement reverses a particular condition requires neither. The cost-of-content is an order of magnitude lower for the misleading version, and the platform reward for both is similar. The equilibrium is predictable.
The Evidence-Based Information Path
Cochrane reviews, Lancet umbrella reviews, JAMA systematic syntheses; pre-registered trials with mandatory outcome reporting.
Years of methodological training; familiarity with statistical caveats and clinical trial limitations; no commercial dependency.
"Effect sizes were small-to-moderate; the evidence base has industry-funding concerns; results may not generalise outside the trial population."
Lower engagement metrics, less viral spread, harder to consume on mobile; loses to fast confident content in attention markets.
Reaches motivated information-seekers, healthcare professionals, and policy contexts; rarely reaches the consumer at the point of purchase.
The Wellness-Influencer Information Path
Personal testimony, podcast episodes, brand-funded "research"; rarely cites primary literature accurately.
Often without formal credentials; commercial dependency on supplement, equipment, or service categories; selects for content that drives sales.
"This protocol changed my life — here are the four steps." Certainty is the engagement currency; nuance is engagement-negative.
High completion rates, comments, shares; recommended into For You feeds; reaches users at moments of vulnerability or aspiration.
Top wellness influencers reach tens of millions monthly; content arrives precisely at the point of purchase, often with affiliate-link conversion paths.
The compare-grid above is not a description of bad actors versus good actors. It is a description of a structural information asymmetry. Even well-intentioned wellness influencers operate within incentive structures that select against careful claims. Even rigorous clinical researchers face distribution disadvantages that prevent their findings from reaching consumers. The asymmetry is the architecture, not the personalities working within it.
The wellness ecosystem has become particularly effective at converting medical authority into commercial signal. Influencers cite peer-reviewed studies — typically the abstract, often without reading the methods or limitations sections — as if the citation establishes the underlying claim. The study is real; the citation is technically accurate; the implication is misleading. The 2024 University of Washington study on misinformation found this pattern characteristic of high-engagement wellness content: real citations, distorted summaries, conclusions that exceed what the studies show.
Counter-strategies are emerging but face structural disadvantages. Health-system-affiliated content creators (Cleveland Clinic on TikTok, Mayo Clinic's social media presence), academic communicators with viral followings, and dedicated medical-misinformation accounts have built modest counter-publics. They face the same algorithmic disadvantages as the underlying evidence. Without platform-level changes — changes that platforms have indicated reluctance to implement — the information asymmetry will persist. The 2026 EU Digital Services Act and the UK Online Safety Act provide some leverage on the largest platforms, but health-misinformation enforcement under those regimes remains nascent.
The honest summary is that consumers cannot easily access evidence-based wellness information through ordinary information channels. They can access it through their primary care physician, through public-health resources (NCCIH, NHS, Cochrane Library, NIH Office of Dietary Supplements), and through a small number of careful science-communication accounts. The information design of the consumer environment does not deliver this material. The wellness industry's commercial strength is built precisely on this gap.
What the Evidence Tells Us
The structural reading of the wellness scorecard
The wellness industry is not a hoax. It is a $6.8 trillion architecture in which a minority of products have meaningful evidence, a larger portion have ambiguous evidence inflated by industry funding, and a substantial third tier has been formally tested and found ineffective — yet continues to sell at scale [1][3][4]. The pattern is not an accident of consumer psychology. It is the predictable output of a regulatory regime, a funding regime, and an information regime each individually permissive, and together commercially decisive.
The first conclusion is taxonomic. The thirteen practices examined in this report sort into three groups, and the sorting matters for individual decisions. ✓ Established-tier practices — exercise, Mediterranean-pattern eating, traditional Finnish sauna at high frequency, time-restricted eating for weight management, evidence-tested mindfulness apps for depression, photobiomodulation for specific dermatology indications — produce real, replicated, clinically meaningful effects. The marketing for these practices typically overstates the magnitude of effect, but the underlying biology is supported. These are reasonable choices for individuals seeking modest improvements in well-defined outcomes.
Tier-strong-but-overstated practices — cold-water immersion for stress reduction, breathwork for inflammation, ashwagandha and rhodiola for stress, infrared sauna for cardiovascular health, certain probiotic strains for specific conditions, collagen for skin in industry-funded trials — produce real but smaller-than-marketed effects, typically with conflict-of-interest concerns. These are reasonable trials for individuals who are clear-eyed about likely effect sizes and unwilling to invest substantial resources without confirmation. The honest framing is "this might help a little, for a while, with these specific outcomes."
Tier-empty practices — blue-light glasses for eye strain or sleep, IV vitamin therapy for healthy people, juice cleanses, jade vaginal eggs, grounding/earthing for medical conditions, hyperbaric oxygen for non-FDA-approved indications, full-body MRI for asymptomatic individuals — have either been tested at high methodological standards and found to produce no clinically meaningful effect, or have never been tested and lack plausible mechanism [3][5][9][15]. The honest framing is "the evidence does not support the claim." Continued sale of these products is a fact about regulatory and information architecture, not about effectiveness.
The wellness industry's commercial advantage is not falsehood. It is the systematic blurring of three distinct evidentiary categories — demonstrated, ambiguous, and absent — under a single marketing register. Consumers cannot easily distinguish them. Regulators address only the most flagrant cases. The information ecosystem distributes high-confidence claims faster than nuanced evidence. The outcome is not consumer error but architectural design — a $6.8 trillion industry whose primary product is the conflation itself.
The second conclusion is structural. The wellness industry is not commercially optional. It now represents 6.1% of global GDP, employs millions, supports a venture capital pipeline, and shapes the information environment in which most consumers form health beliefs. Reform is not a matter of consumer education alone — though that helps — and not a matter of more aggressive regulatory action alone — though that also helps. It requires changes to evidence architecture (mandatory pre-registration of supplement trials, independent funding mechanisms, mandatory outcome reporting), to the information ecosystem (algorithmic accountability for health misinformation, mandatory disclosure of commercial relationships), and to the regulatory boundary (closing the structure-function loophole, federal licensure for wellness services). None of these is on near-term political timetables in the major markets.
The third conclusion is individual. For consumers attempting to navigate the wellness market, the evidence supports a specific decision rule: assign higher prior weight to interventions with robust independent evidence (exercise, sleep, diet quality, vaccination, evidence-based mental healthcare), lower prior weight to interventions with smaller or industry-funded evidence bases, and minimal prior weight to interventions that have been formally tested and found wanting. The decision rule is not novel — it is the standard evidence-based-medicine approach. What is novel is the marketing environment that systematically obscures it.
The fourth conclusion concerns the role of the practitioner. Primary care clinicians, registered dietitians, and clinical psychologists are positioned to function as the consumer's interface with the evidence base — but only if they are themselves resourced to do so. Time pressure on primary care visits, gaps in continuing-education curricula on supplement and wellness practices, and growing patient expectations imported from the wellness ecosystem combine to produce a clinical environment where the practitioner is often less equipped than the patient to interrogate a wellness claim. Investment in clinician resources — accessible evidence summaries, decision aids for common wellness queries, time within visits to address them — would substantially improve consumer protection. It is not happening at scale.
The fifth conclusion concerns the conceptual frame. Wellness is not the opposite of medicine. The two share founders, journals, conferences, and academic appointments. The boundary between them is regulatory and commercial, not biological. The same intervention — say, time-restricted eating — appears as evidence-based medicine in one context and as marketed wellness in another. The collapse of this boundary is, in some respects, a productive development: many evidence-based practices were dismissed by mainstream medicine for decades and were preserved within wellness traditions before re-entering medical literature. The cost is the loss of evidentiary discipline. The synthesis the industry has yet to produce is one in which both registers can coexist with their distinct evidentiary commitments intact.
The wellness industry exists because demand exists. People feel unwell, anxious, depleted, or aging, and they will spend money to address those states. Medicine has historically been undersupplied to address them — too disease-focused, too acute-care-oriented, too time-pressured. The wellness industry filled that gap. The question is not whether the industry should exist but what evidentiary discipline it should be held to. The evidence in this report suggests the current answer — much less than pharmaceutical medicine — produces a market in which a substantial fraction of products do not work and consumers cannot easily tell which are which. That is a fixable problem. It has not been fixed.
What the evidence tells us, in the end, is that the consumer needs better information architecture, the clinician needs better resources, the regulator needs better authority, and the industry needs better incentives. None of these is impossible. None of them is in train. Until they are, the scorecard above remains the most useful tool an individual consumer can carry into the wellness marketplace: a tier-graded map of what works, what might, and what almost certainly does not.